- Personalis, Inc. (PSNL, Financial) to present latest data at ASCO Annual Meeting in Chicago, Illinois.
- Presentations focus on NeXT Personal® ultrasensitive ctDNA assay for cancer detection.
- Key studies explore applications in breast and cervical cancer.
Personalis, Inc. (PSNL), a leader in advanced genomics for precision oncology, announced that it will present several significant findings at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago, Illinois. The presentations will spotlight clinical studies employing the NeXT Personal® ultrasensitive ctDNA assay, a tool designed for the detection of residual and recurrent cancer.
The NeXT Personal® assay aims to enhance the sensitivity and accuracy of cancer detection, providing valuable insights for guiding treatment decisions. Key presentations include the TBCRC 040 (PREDICT-DNA trial), which investigates circulating tumor DNA and survival post-neoadjuvant therapy for breast cancer, and the Phase 3 CALLA trial focused on cervical cancer.
Dr. Richard Chen, Chief Medical Officer and Executive Vice President, R&D at Personalis, emphasized the company's commitment to advancing cancer management through earlier and more sensitive detection of cancer recurrence. Other notable presentations will cover topics such as prognostication in triple-negative breast cancer post-chemotherapy and early predictors of immunotherapy success in advanced cancer.
These presentations are critical in furthering the clinical application and development of the NeXT Personal® assay, potentially influencing treatment strategies for various cancer types. For more information on Personalis, Inc., and their research developments, visit their official website.
